Servier receives a positive CHMP opinion for ONIVYDE® in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as first line therapy in patients with metastatic pancreatic adenocarcinoma.
Newsroom
NEWS
All our latest news
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
CStone sells to Servier its exclusive rights to TIBSOVO®in Greater China and Singapore